Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage biopharmaceutical company focusing on drug creation and novel delivery systems. Their work spans new chemical entities and novel drug delivery systems (NDDS) for global markets.

SPARC engages in strategic licensing agreements, enabling Sun Pharma to commercialize drugs like Xelpros and Elepsia XR in the US market, showcasing the collaborative link between the two companies.

The company has faced multiple regulatory hurdles, particularly with facilities flagged by USFDA for non-compliance, impacting drug approvals and delaying royalty income.

SPARC's strategy includes global partnerships, granting exclusive rights for its assets to companies such as Visiox Pharma and China Medical Systems Ltd. to tap into international markets.

Recent financial restructuring through equity conversion has altered SPARC's ownership structure, reducing the stake of its former holding company.